Inmagene files two international patent applications

SHANGHAI and SAN DIEGO andHANGZHOU,China,Nov. 17,2021 -- Inmagene Biopharmaceuticals ("Inmagene" or the "Company") announced that it has filed two international patent applications for its drug candidates,IMG-007 (OX40 antagonist) and IMG-008 (IL-36R antagonist). One application covers IMG-008's molecular sequence and the other covers improved development in IMG-007's formulation. Inmagene controls the global rights to develop and commercialize both drug candidates.

These are the first of a series of patent applications being prepared by Inmagene,demonstrating the Company's strong innovation capabilities. Guided by global scientific and clinical intelligence,leveraging the potential for China's high-efficiency drug development resources,Inmagene is advancing 12 "smart" innovation programs,creating new drug candidates,such as IMG-008,from scratch.

About Inmagene

Inmagene,with wholly owned subsidiaries in San Diego,Shanghai,Hangzhou and Wuhan,is a global clinical-stage biotech company focused on developing novel therapeutics for immunology-related diseases. Believing in "borderless innovation",the Inmagene team strives to integrate efficient resources worldwide to make such therapeutics available to patients globally. The Company is building a robust development pipeline of nearly 20 drug candidates,one of which,Izokibep (IMG-020),has entered global phase 2 trials for multiple indications.

Inmagene is operating 12 "smart" innovation programs to create and develop novel drug candidates for the global market. It also in-licenses drug candidates for the Asia markets and,together with its partners,carries out global development activities,including multi-center clinical trials. Inmagene has formed strategic partnerships with Affibody AB,TWIB and Kissei to develop and commercialize 7 highly innovative drug candidates.

About IMG-007 (OX40 antagonist)

IMG-007,an antibody targeting OX40,is a drug candidate for autoimmune diseases,such as graft versus host disease,asthma,atopic dermatitis,rheumatoid arthritis and inflammatory bowel disease. Preclinical trial data has demonstrated that IMG-007 has superior activity as compared to a leading competitor. IMG-007,in-licensed from HUTCHMED (Nasdaq/AIM: HCM),is under CMC and toxicological development and the Company plans to submit IMG-007's IND application by the first half of 2022.

About IMG-008 (IL-36R antagonist)

IMG-008,internally-created by Inmagene,is an antibody targeting IL-36R. It is a drug candidate for autoimmune diseases,including palmoplantar pustulosis,ichthyosis,hidradenitis suppurativa,inflammatory bowel disease and generalized pustular psoriasis. Preclinical results have demonstrated that IMG-008 has a longer half-life,higher exposure,and stronger activity as compared to a leading competitor. The Company plans to submit IMG-008's IND application in the second half of 2022.

For additional information,please visitwww.inmagenebio.com

View original content:https://www.prnewswire.com/news-releases/inmagene-files-two-international-patent-applications-301426498.html